Abstract 1912
Background
The overall benefit from systemic treatments in advanced STS remains modest despite advances in cancer therapies. PDX models may help as avatars in guiding individualized drug use decisions.
Methods
In this prospective single center trial, fresh tumors from patients (pts) with suspected or recently diagnosed STS were engrafted into immunodeficient mice avatars (TumorGraft; Champions Oncology) and tested against a number of standard or non-licensed agents. PDX drug sensitivity profiles were then compared with real-life treatment outcomes.
Results
Of 18 patients enrolled, 3 patients were excluded (consent withdrawal/non-sarcomas). Patient baseline characteristics are summarized in the table. Rate of engraftment was 40% (6/15 pts), while the median time from biopsy to availability of drug sensitivity profile was 379 days (186 – 421). In patients with available drug sensitivity profile (9 different drugs involving 6 pts), the mouse avatar correctly predicted the drug efficacy or lack thereof of drugs in 7 of 9 drug selection time-points (78%) and in 5 of 6 patients (83%).Table:
1718P Patient baseline characteristics
Item | Eligible patients (n = 15) | Engrafted patients (n = 6) |
---|---|---|
Median age (range) | 57 (23-76) | 57 (45-69) |
Gender (M:F) | 8:7 | 3:3 |
Subtype - Liposarcoma - Leiomyosarcoma -UPS -Others | 5 3 1 6 | 2 2 1 1 |
Conclusions
PDX avatars can accurately predict drug response in STS pts. The rate of engraftment and time taken to produce drug sensitivity profiles are limitations for using this platform in guiding treatment for individual patients in real time. Nonetheless, the high degree of clinical predictability of this PDX platform may offer therapeutic value for personalized oncology approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Albiruni Razak.
Funding
Mount Sinai Sarcoma Foundation.
Disclosure
G. Paris: Full / Part-time employment: champions oncology. M. Mancini: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Champions Oncology. A.R.R. Albiruni: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): Lilly; Advisory / Consultancy, Research grant / Funding (self): Merck; Research grant / Funding (self): CASI Pharmaceuticals; Research grant / Funding (self): Novartis; Research grant / Funding (self): Deciphera; Research grant / Funding (self): Kayopharm Therapeutics; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Roche/ Genentech; Research grant / Funding (self): Boston Biomedical; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): MedImmune; Research grant / Funding (self): Amgen; Research grant / Funding (self): GlaxoSmithKline; Research grant / Funding (self): Blueprint Medicines; Research grant / Funding (self): AbbVie; Research grant / Funding (self): Adaptimmune. All other authors have declared no conflicts of interest.
Resources from the same session
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract
3690 - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Presenter: Kyoungmin Lee
Session: Poster Display session 1
Resources:
Abstract
2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.
Presenter: Heejung Chae
Session: Poster Display session 1
Resources:
Abstract
5021 - Soft tissue sarcomas express a distinct mRNA immune profile
Presenter: Viktor Grünwald
Session: Poster Display session 1
Resources:
Abstract
3029 - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Presenter: Mehdi Brahmi
Session: Poster Display session 1
Resources:
Abstract
3914 - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Presenter: Lauren Mc Connell
Session: Poster Display session 1
Resources:
Abstract
5097 - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.
Presenter: Candice Merle
Session: Poster Display session 1
Resources:
Abstract
1383 - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3
Presenter: Xu Jiang
Session: Poster Display session 1
Resources:
Abstract
3386 - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern
Presenter: Dominga Racanelli
Session: Poster Display session 1
Resources:
Abstract
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract